10:51 uur 09-01-2019

JPND lanceert vraag naar 30 miljoen euro voor multinationaal onderzoek naar gepersonaliseerde geneeskunde voor neurodegeneratieve ziekten

Het EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative heeft een gezamenlijke transnationale oproep aangekondigd voor multinationaal onderzoek naar gepersonaliseerde geneeskunde voor neurodegeneratieve ziekten.

PARIJS–(BUSINESS WIRE)–Neurodegeneratieve ziekten zijn slopende en nog steeds grotendeels onbehandelbare aandoeningen. Deze ziekten worden gekenmerkt door een grote variatie in oorsprong, mechanismen en klinische expressie, en vragen om behandelingen die rekening houden met al deze bijzondere kenmerken. Het ontcijferen van deze variabiliteit is een van de grootste uitdagingen bij de behandeling van neurodegeneratieve ziekten. De weg voorwaarts schuilt in ‘Precision Medicine’, ondersteund door gepersonaliseerde benaderingen. Die combinatie biedt het grootste voordeel voor patiënten.

JPND Launches €30 Million Call for Multinational Research on Personalised Medicine for Neurodegenerative Diseases

The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has announced a joint transnational call for multinational research on personalised medicine for neurodegenerative diseases.

PARIS–(BUSINESS WIRE)– Neurodegenerative diseases are debilitating and still largely untreatable conditions. These diseases are characterised by a large variability in their origins, mechanisms and clinical expression, requesting treatments that will need to take into account all these specificities. Deciphering this variability is one of the biggest challenges in the treatment of neurodegenerative diseases and the way forward is Precision Medicine, supported by highly personalised approaches for the greatest benefit of the patients.

In partnership with the European Commission, JPND is inviting multinational research teams to submit proposals for ambitious, innovative and multidisciplinary collaborative research projects to change the trajectory of these diseases through the development of Precision Medicine approaches.

JPND has chosen to focus in the area of Precision Medicine, which relates to the targeting of specific elements responsible for pathology in a given individual at a particular point in time. It is an emerging approach for disease prevention, diagnosis and treatment that takes into account individual variability in genes, biological/molecular characteristics together with environmental and lifestyle factors.

According to Professor Philippe Amouyel, University of Lille (France) and Chair of the JPND Management Board:
“During the last ten years, researchers have progressively uncovered the high complexity and wide diversity of neurodegenerative diseases. We need now to complete and use this massive amount of knowledge to develop targeted approaches to more efficiently fight the dramatic progression of these diseases.”

According to Professor Thomas Gasser, University of Tübingen (Germany) and Chair of the JPND Scientific Advisory Board:
“Progresses in precision medicine will be a unique way to develop innovative approaches to prevent, slow and cure neurodegenerative diseases. This call aims to harness the necessary expertise across Europe and globally, to address this research challenge. ”

Professor Amouyel added: “With this in mind, JPND participating countries in close collaboration with the European Commission have identified precision medicine as a major issue to tackle the global challenge of neurodegenerative diseases.”

Proposals submitted under this call must focus on Precision Medicine in one or several of the following research areas:

    • Diagnosis (e.g. biomarkers, imaging data, omics approaches, big data analyses).
    • Prevention (e.g. biomarkers for studying novel treatments and interventions, co-morbidities, digital technologies, stratification within cohort studies and clinical trials).
    • Care (e.g. improvement of social and health care systems, molecular profiling, imaging, lifestyle data).

Proposals must also relate to any or several of the following neurodegenerative diseases: Alzheimer’s disease and other dementias, Parkinson’s disease and PD-related disorders, Prion diseases, Motor Neuron diseases, Hungtington’s disease, Spinocerebellar ataxia and Spinal muscular atrophy.

Pre-proposals must be submitted no later than 15:00h C.E.T. on March 12, 2019.

For more information about the call, please click here.


Press contact
Karin YEO
+33 7 8227 2887
Twitter: @JPNDEurope

Check out our twitter: @NewsNovumpr